Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR- 122, AFP and PIVKA-II.
CONCLUSIONS: In HBV-related cirrhosis, the combination of miR-122, AFP and PIVKA-II enables the identification of patients at higher risk of HCC development that could benefit from closer monitoring.
PMID: 28650134 [PubMed - as supplied by publisher]
Source: Panminerva Medica - Category: General Medicine Tags: Panminerva Med Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemistry | Cirrhosis | General Medicine | Hepatocellular Carcinoma | Liver | Liver Cancer | Study | Urology & Nephrology | Vitamins